Technology | December 05, 2011

FDA Approves First Generic Version of Cholesterol-Lowering Drug Lipitor


December 5, 2011 – The U.S. Food and Drug Administration (FDA) approved the first generic version of the cholesterol-lowering drug Lipitor (atorvastatin calcium tablets).

Ranbaxy Laboratories Ltd. has gained approval to make generic atorvastatin calcium tablets in 10 milligram, 20 mg, 40 mg, and 80 mg strengths. The drug will be manufactured by Ohm Laboratories in New Brunswick, N.J.

People who have high blood cholesterol levels have a greater chance of getting heart disease. By itself, the condition usually has no signs or symptoms. Thus, many people do not know that their cholesterol levels are too high.

"This medication is widely used by people who must manage their high cholesterol over time, so it is important to have affordable treatment options," said Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research. "We are working very hard to get generic drugs to people as soon as the law will allow."

Not all cholesterol in your blood is bad. There are three kinds of blood cholesterol that you should know about: high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides. HDL (good cholesterol) helps keep cholesterol from building up in the arteries. LDL (bad cholesterol) is the main source of cholesterol buildup and blockage in the arteries, which can prevent proper blood flow to your heart and lead to a heart attack. Triglycerides can lead to hardening of the arteries.

Atorvastatin is a statin, a type of drug that lowers cholesterol in the body by blocking an enzyme in the liver. Atorvastatin is used along with a low-fat diet to lower the LDL cholesterol and triglycerides in the blood. The drug can raise HDL cholesterol as well. Atorvastatin lowers the risk for heart attack, stroke, certain types of heart surgery, and chest pain in patients who have heart disease or risk factors for heart disease such as age, smoking, high blood pressure, low HDL or family history of early heart disease.

In the clinical trials for Lipitor, the most commonly reported adverse reactions in patients were: inflammation of the nasal passages, joint pain, diarrhea and urinary tract infection.

Generic drugs approved by FDA have the same high quality and strength as brand-name drugs. The generic manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs.

Information about the availability of generic atorvastatin can be obtained from Ranbaxy.  

For more information: www.fda.gov

 


Related Content

News | Pharmaceuticals

July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that ...

Home July 10, 2024
Home
News | Pharmaceuticals

June 5, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data ...

Home June 05, 2024
Home
News | Pharmaceuticals

May 24, 2024 — Lexicon Pharmaceuticals, Inc. announced a new post-hoc analysis of clinical data showing that INPEFA ...

Home May 24, 2024
Home
News | Pharmaceuticals

May 6, 2024 — Tenax Therapeutics, Inc., a Phase 3, development-stage pharmaceutical company focused on identifying ...

Home May 06, 2024
Home
News | Pharmaceuticals

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
News | Pharmaceuticals

January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...

Home January 25, 2024
Home
News | Pharmaceuticals

November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

Home November 21, 2023
Home
Feature | Pharmaceuticals | By Christine Book

In a new 3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA, Managing Editor ...

Home October 25, 2023
Home
Videos | Pharmaceuticals

In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...

Home September 26, 2023
Home
Subscribe Now